此图片来自微信公众平台 未经允许不可引用 al larger in make and the many of the country of the states of the states of the status and the station of the status and the station of the station of the states of the st 此图片来自微信公众平台 未经允许不可引用 此图片来自微信公众平台 未经允许不可引用 ...

（原标题：科学减重，健康轻盈！一起认识"食物噪音"） 0:00 ...

（原标题：诺和诺德参加第十二届广州塔国际登高赛 健康轻盈燃爆小蛮腰） 10月19日，第十二届广州塔国际登高赛燃情开赛！3000 名海内外选手集结，共同冲击 "全国最高塔" 小 蛮腰，最终全员成功登顶，场面超燃超震撼！健康嘉年华聚焦"科学减重 健康轻盈"，打破食物噪音困 扰，吸引全场目光。 活动现场，广州星弧合唱团用一首改编歌曲《科学减重 健康轻盈》唱出很多人被"食物噪音"困扰的心 声。从这里开始，让我们一起学习为食物噪音按下"静音键"，找回对健康生活的掌控感。 据悉，广州塔国际登高赛已连续举办十二年，作为迄今为止全球最大规模、全国最具影响力的地标登高 赛事，宣传影响已覆盖超10亿人次。本届赛事由南方财经全媒体集团和广州市城投集团共同指导，广东 广播电视台经济科教频道、广州塔、广东省二十一世纪教育基金会共同主办，光大银行、诺和诺德公益 支持。汇聚广东省卫生健康宣传教育中心主任王剑莉、马拉松世界冠军、中国女子全马纪录保持者孙英 杰及来自全国各地的30余位专家。 活动现场不仅有热血沸腾的登高竞技，由诺和诺德公益支持的健康嘉年华同样成为全场焦点。活动紧扣 时下热门的"体重管理"议题，通过设立健康检测区、科普展板及合唱 ...

活动现场不仅有热血沸腾的登高竞技，由诺和诺德公益支持的健康嘉年华同样成为全场焦点。活动紧扣 时下热门的"体重管理"议题，通过设立健康检测区、科普展板及合唱表演等形式，为市民与选手带来了 一场别开生面的健康科普盛宴，让"食物噪音"这个关键词，成为全场热议的C位热词。 肥胖症是一种复杂的慢性疾病，且会不断进展。在中国，半数以上成年人存在超重或肥胖问题。暨南大 学附属第一医院王存川教授指出："肥胖与超过200种并发症相关，包括心血管疾病、某些癌症和2型糖 尿病等。此外，肥胖症患者还常遭受污名化、歧视及面临心理健康问题。" 10月19日，第十二届广州塔国际登高赛燃情开赛！3000名海内外选手集结，共同冲击"全国最高塔"小蛮 腰，最终全员成功登顶。 广州塔国际登高赛已连续举办十二年，作为迄今为止全球最大规模、全国最具影响力的地标登高赛事， 宣传影响已覆盖超10亿人次。本届赛事由南方财经全媒体集团和广州市城投集团共同指导，广东广播电 视台经济科教频道、广州塔、广东省二十一世纪教育基金会共同主办，光大银行、诺和诺德公益支持。 （文章来源：证券日报） 王存川表示："食物噪音并非指实际的声音，而是一种大脑中难以抑制的、持续出现 ...

一天到晚总想着吃东西？这可能是食物噪音搞的鬼，如何让它安静下来，别吵到你的减肥大业？ ...

Core Viewpoint - The recent INFORM survey indicates that semaglutide not only significantly aids in weight loss but also effectively reduces "food noise," which refers to intrusive thoughts about food that can impact mental health [4][5][10]. Group 1: Survey Results - 46% of participants reported a reduction in persistent food-related thoughts after using semaglutide, with the prevalence dropping from 62% to 16% [7][10]. - The percentage of respondents feeling that food noise negatively affected their lives decreased from 60% to 20% [7][10]. - 64% of participants noted improvements in their mental health since starting semaglutide, while 76% adopted healthier lifestyles and 80% developed healthier habits [7][10]. Group 2: Implications for Mental Health - Food noise, characterized by persistent and intrusive thoughts about food, is common among individuals with obesity and can lead to feelings of guilt, shame, and anxiety, thereby hindering weight loss efforts [8][10]. - The findings from the survey suggest that semaglutide not only supports weight loss but also alleviates food noise, enhancing mental well-being and promoting healthier lifestyle choices [5][7]. Group 3: Future Research Directions - Novo Nordisk is continuing to investigate how obesity affects daily life, with upcoming presentations focusing on the impact of semaglutide on dietary behavior and control [8].

Group 1 - The core finding from the real-world study presented by Novo Nordisk at the EASD conference indicates that 46% of patients using semaglutide (brand name: Ozempic) reported a significant reduction in "food noise," which refers to uncontrollable thoughts about food [2] - Semaglutide, a GLP-1 drug, works by suppressing appetite, slowing gastric emptying, and inducing a feeling of fullness, thereby aiding weight loss [2] - Novo Nordisk's recent data shows that 84.5% of weight loss in patients was derived from body fat, preserving muscle function, which is crucial for maintaining overall health during weight loss [3] Group 2 - Novo Nordisk is actively addressing competition from Eli Lilly and has recently announced a large-scale global layoff, resulting in an over 11% increase in its stock price within a week [3] - The company aims to enhance decision-making efficiency and accelerate clinical pipeline progress, as stated by its Chief Scientific Officer Martin Holst Lange [3] - Novo Nordisk is exploring treatments for various obesity-related complications and is validating the efficacy of its weight loss drug for Alzheimer's disease, with expectations to obtain clinical data by the end of 2025 [3] - Positive clinical trial results for the Alzheimer's study could potentially generate up to $15 billion in additional annual revenue for Novo Nordisk, according to UBS analysis [3]

Core Insights - Novo Nordisk presented real-world research results on the use of semaglutide for weight loss at the EASD annual meeting, indicating that 46% of patients reported a significant reduction in "food noise" after treatment [1][3] - The company reported that 84.5% of weight loss from semaglutide comes from body fat, preserving muscle function, which is crucial for overweight or obese patients [3] - Novo Nordisk is facing competition from Eli Lilly and has recently announced significant layoffs, resulting in an over 11% increase in stock price within a week [3] - The company is exploring treatments for various obesity-related conditions and is validating the efficacy of its weight loss drug for Alzheimer's disease, with potential annual revenue of up to $15 billion if clinical trials succeed [4] Company Developments - Novo Nordisk aims to enhance decision-making efficiency and accelerate clinical pipeline progress following recent layoffs [3] - The company is developing therapies targeting a range of conditions associated with obesity, including arthritis and sleep apnea [4] - The ongoing large-scale clinical study for Alzheimer's disease is the first of its kind for GLP-1 drugs, with results expected by the end of 2025 [4]

Group 1 - The INFORM study presented at the EASD 2025 conference indicates that the use of the weight management version of semaglutide significantly reduces "food noise" among participants, leading to improvements in mental health and lifestyle [1] - The proportion of patients troubled by "food noise" decreased by 46% during treatment, with 60% reporting negative impacts before treatment, dropping to 20% during treatment [1] - 64% of respondents reported improvements in mental health, with 76% adopting healthier lifestyles and 80% developing better habits; 83% expressed satisfaction with the treatment outcomes [1] Group 2 - The STEP UP trial subgroup analysis shows that patients receiving semaglutide (7.2mg) experienced significant reductions in food cravings, emotional eating, and loss of control over eating compared to the placebo group [2] - The trial demonstrated an average weight reduction of 21% for participants on the higher dose of semaglutide, with one-third achieving a weight loss of 25% or more [2] - The analysis indicates that the weight loss achieved with semaglutide (7.2mg) primarily consists of fat loss (84.5%), which is beneficial for improving body composition and maintaining physical function in overweight or obese patients [2]